Advertisement

Search Results

Advertisement



Your search for ,WhO matches 21072 pages

Showing 3301 - 3350


gynecologic cancers
immunotherapy

Highlights of the SGO 2023 Annual Meeting on Women’s Cancer

The sun was out, and the weather was beautiful for the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer held in Tampa, Florida, in March 2023. Participants came from across the world for this second hybrid gathering since the COVID-19 pandemic to share ongoing advances in ...

issues in oncology
pain management

Study Finds Cancer-Related Emergency Department Visits Increased by 67%, Mainly Because of Uncontrolled Pain

Emergency department (ED) visits by patients with cancer increased by 67.1% between the start of 2012 and the end of 2019, compared with an increase of just 7.5% in cancer incidence, according to a recent study in JAMA Network Open.1 Factors identified as possible explanations for the...

lung cancer

Detection of Early Emphysema During Lung Cancer Screening: Opportunities to Optimize Health

In an article in Annals of the American Thoracic Society, James L. Mulshine, MD, of the Center for Healthy Aging, Department of Medicine, Rush University, and colleagues maintained that the high frequency of emphysema newly identified during low-dose computed tomography (CT) lung cancer screening...

lung cancer

ASCO Releases Guideline Updates for Stage IV NSCLC With and Without Driver Alterations

ASCO has updated two living guidelines on the systemic treatment of stage IV non–small cell lung cancer (NSCLC) with and without driver alterations with the inclusion of new evidence-based treatment recommendations.1,2 Among the updates, the guidelines add the recently approved RAS GTPase family...

breast cancer

Novel Hormone Receptor–Driven Therapies Tackling Endocrine Resistance in Breast Cancer

In hormone receptor–positive metastatic breast cancer, tumors eventually become resistant not only to endocrine blockade but to inhibitors of cyclin-dependent kinases 4 and 6 (CDK4/6). This obstacle to successful treatment is being tackled with novel hormone receptor–directed therapies, with the...

AACR Announces Fellows of the AACR Academy Class of 2023

The American Association for Cancer Research (AACR) recently announced its newly elected class of Fellows of the AACR Academy. Fellows of the AACR Academy serve as a global brain trust of top contributors to cancer science and medicine who help advance the mission of the AACR to prevent and cure...

Expert Point of View: Jarushka Naidoo, MBBCh, MHS

Invited discussant Jarushka Naidoo, MBBCh, MHS, Professor of Medical Oncology and Consultant Medical Oncologist, Beaumont RCSI Cancer Centre, in Dublin, called the results of amivantamab-vmjw therapy in patients with EGFR exon 20 insertion–positive advanced non–small cell lung cancer (NSCLC)...

lung cancer

Amivantamab Shows Efficacy in Advanced NSCLC With EGFR Exon 20 Insertions

Amivantamab-vmjw, an EGFR and MET bispecific monoclonal antibody, has demonstrated encouraging long-term benefits and consistent efficacy in patients with advanced non–small cell lung cancer (NSCLC) with EGFR exon 20 insertions, according to data presented by Pilar Garrido, MD, PhD, Associate...

Expert Point of View: Daniel SW Tan, BSc, MBBS, PhD

Invited discussant of the phase II APPLE trial, Daniel SW Tan, BSc, MBBS, PhD, of the National Cancer Centre Singapore, noted that 17% of patients have had only molecular disease progression and were switched over to the sequential strategy. “This may be in some parts related to the sensitivity of...

lung cancer

Front-Line vs Sequential Use of Osimertinib in EGFR-Mutant NSCLC: Potential Impact of Liquid Biopsies

Using liquid biopsies to detect circulating tumor DNA (ctDNA) may soon transform treatment strategies for patients with advanced EGFR-mutant non–small cell lung cancer (NSCLC), according to data presented during the European Lung Cancer Congress 2023 by lead study author Jordi Remon, MD, PhD, of...

lung cancer

CheckMate 816: 3-Year Update Shows Improved Event-Free Survival With Neoadjuvant Nivolumab and Chemotherapy for Resectable NSCLC

The combination of neoadjuvant nivolumab plus chemotherapy continues to demonstrate potential as a standard treatment for patients with resectable non–small cell lung cancer (NSCLC), according to data presented during the European Lung Cancer Congress 2023.1 The 3-year update from the phase III...

lung cancer

CodeBreaK 200: Sotorasib Offers Improved Quality of Life for Patients With Previously Treated NSCLC

The latest research on sotorasib, a targeted therapy for KRAS G12C–mutated non–small cell lung cancer (NSCLC), reveals that patients may experience better quality of life while benefiting from improved clinical outcomes. Analysis of patient-reported outcomes presented during the European Lung...

Olivier Delattre, MD, PhD, Honored With 2023 AACR–St. Baldrick’s Foundation Award

The American Association for Cancer Research (AACR) presented Olivier Delattre, MD, PhD, with the 2023 AACR–St. Baldrick’s Foundation Award for Outstanding Achievement in Pediatric Cancer Research during the AACR Annual Meeting 2023 in April in Orlando, Florida. Dr. Delattre is Director of the...

Expert Point of View: Debra L. Richardson, MD and Joyce F. Liu, MD, MPH

Debra L. Richardson, MD, Associate Professor and Chief of the Section of Gynecologic Oncology, Oklahoma TSET Phase I Program, at the Stephenson Cancer Center, University of Oklahoma, Oklahoma City, discussed the emerging field of antibody-drug conjugates at a session on platinum-resistant ovarian...

gynecologic cancers

Final SORAYA Analysis Supports Mirvetuximab Soravtansine in Ovarian Cancer

Treatment with the folate receptor alpha (FRα)-targeted antibody-drug conjugate mirvetuximab soravtansine-gynx benefited patients with FRα-high, platinum-resistant ovarian cancer, even after multiple lines of prior therapy, according to an updated analysis of the SORAYA trial presented at the...

Expert Point of View: Jaffer A. Ajani, MD

Jaffer A. Ajani, MD, Professor of Medicine in the Department of Gastrointestinal Oncology at The University of Texas MD Anderson Cancer Center, told The ASCO Post that obesity (defined as high body mass index of 30–39.9 kg/m2) is increasing around the globe; by 2035, more than 50% of adults will...

skin cancer

Study Shows mRNA-Based Personalized Vaccine Plus Pembrolizumab Active in Melanoma for the First Time

The search for an effective cancer vaccine has been frustrating, but finally there may be light at the end of the tunnel. Adjuvant use of an investigational personalized mRNA vaccine (mRNA-4157) plus the PD-1 inhibitor pembrolizumab improved recurrence-free survival vs pembrolizumab alone in...

breast cancer

USPSTF Issues Draft Recommendation Statement on Screening for Breast Cancer: All Women Should Be Screened Every Other Year, Beginning at Age 40

On May 9, the U.S. Preventive Services Task Force (USPSTF) posted a draft recommendation statement on screening for breast cancer. The USPSTF now recommends that all women get screened for breast cancer every other year starting at age 40 years (this is a B grade recommendation, meaning the USPSTF...

solid tumors
supportive care

Bariatric Surgery May Reduce Risk of Obesity-Related Cancers by More Than Half

Researchers have found that patients who are obese and undergo bariatric surgery may have a greater than 50% decreased incidence rate of obesity-related cancer compared with patients who did not have the weight-loss procedure, according to new findings presented by Chittajalu et al at Digestive...

hepatobiliary cancer
colorectal cancer
issues in oncology

Three New Studies Unveil Recent Developments in the Screening and Treatment of Biliary Tract Cancer and Colorectal Cancer

Researchers have revealed the impacts of several new developments in screening and treating patients with biliary tract cancer and colorectal cancer—including the development of patient-derived organoids to test chemotherapy response, the use of nonsteroidal anti-inflammatory drugs (NSAIDs) to...

breast cancer

Extension of Adjuvant Anastrozole After Initial Therapeutic Regimen in Postmenopausal Patients With Hormone Receptor–Positive Breast Cancer

In a Japanese phase III trial (AERAS) reported in the Journal of Clinical Oncology, Iwase et al found that an additional 5 years of adjuvant anastrozole after 5 years of anastrozole or tamoxifen followed by anastrozole was associated with improved disease-free survival vs no further anastrozole...

lymphoma

Does Stem Cell Transplantation Extend Survival in Patients With Advanced Cutaneous T-Cell Lymphomas?

In a French study (CUTALLO) reported in The Lancet, de Masson et al found that patients with advanced-stage cutaneous T-cell lymphomas who were able to undergo allogeneic hematopoietic stem cell transplantation (HSCT) had prolonged progression-free survival vs matched patients receiving...

gynecologic cancers

The Role of Salpingectomy in Ovarian Cancer: Standard of Care or Targeted Therapy?

No one doubts the deadly nature of high-grade serous ovarian cancer. This histologic subtype is responsible for most ovarian cancer deaths, representing the eighth leading cause of cancer deaths in women worldwide and the fifth in the United States. Although there has been some progress in...

lung cancer

Lung Cancer Screening and Possible Unappreciated Benefits

Screening that reduces cancer mortality serves as a foundational element of impactful care for certain cancers. That said, harms related to screening deserve our attention—overdiagnoses; diagnostic odysseys that may be invasive, expensive, or even unintentionally harmful; overtreatment of diagnosed ...

Expert Point of View: Roy S. Herbst, MD, PhD

Invited discussant Roy S. Herbst, MD, PhD, Deputy Director of the Yale Cancer Center, New Haven, Connecticut, called this “a very exciting abstract exploring when surgery meets immunotherapy.” He commented: “NSCLC is a big disease, affecting 2 million or more people worldwide, and this is the tip...

lung cancer

AEGEAN Trial Shows Benefit With Immunotherapy-Based Combination for NSCLC

Patients with treatment-naive resectable non–small cell lung cancer (NSCLC) treated with neoadjuvant durvalumab plus chemotherapy and adjuvant durvalumab monotherapy had improved event-free survival and pathologic complete response rates compared with those who received neoadjuvant chemotherapy...

multiple myeloma
issues in oncology

Enrollment Criteria for Multiple Myeloma Clinical Trials May Exclude Patients From Racial and Ethnic Minorities

The parameters set to determine which patients can enroll in clinical trials testing new multiple myeloma treatments may disproportionately exclude patients from racial and ethnic minority groups, according to a new study published by Kanapuru et al in the journal Blood. Background Multiple myeloma ...

breast cancer
issues in oncology

Antibacterial Treatment May Resolve Acute Radiation Dermatitis in Patients With Breast Cancer Undergoing Radiation Therapy

Researchers have found that acute radiation dermatitis may involve the skin bacterium Staphylococcus aureus and that a simple, low-cost treatment may prevent severe cases in patients undergoing radiation therapy, according to two novel studies published by Kost et al—one a randomized clinical trial ...

leukemia

Induction Failure in Pediatric and Young Adult Patients With T-Cell ALL

In an analysis reported in the Journal of Clinical Oncology, O’Connor et al found that pediatric and young adult patients with T-cell acute lymphoblastic leukemia (T-ALL) who did not respond to induction therapy had poorer outcomes vs those with induction response. The investigators also attempted...

lung cancer
genomics/genetics

Sotorasib in Pretreated Patients With KRAS G12C–Mutated NSCLC: 2-Year Analysis of CodeBreaK100

In an analysis published in the Journal of Clinical Oncology, Grace K. Dy, MD, and colleagues report 2-year outcomes of the CodeBreaK100 phase I/II trial of sotorasib in previously treated patients with KRAS G12C–mutated locally advanced or metastatic non–small cell lung cancer (NSCLC). According...

hepatobiliary cancer
pancreatic cancer
solid tumors

KRYSTAL-1 Update: Adagrasib Yields Benefit in Variety of KRAS G12C–Mutated Tumors

In the phase I/II KRYSTAL-1 trial, the KRAS inhibitor adagrasib demonstrated clinical activity in previously treated patients with pancreatic ductal adenocarcinoma, biliary tract cancer, and other solid tumors harboring KRAS G12C mutations, according to research presented at the ASCO Plenary Series ...

gastroesophageal cancer
gastrointestinal cancer
pancreatic cancer
colorectal cancer
hepatobiliary cancer

Risk of Early-Onset Digestive Tract Cancers Among Young Adults With Nonalcoholic Fatty Liver Disease

In a Korean nationwide cohort study reported in the Journal of Clinical Oncology, Park et al found that individuals aged 20 to 39 years with nonalcoholic fatty liver disease (NAFLD) were at an increased risk of developing early-onset digestive tract cancers. Study Details The study included data on ...

colorectal cancer
issues in oncology

Newly Identified Risk Factors May Point to a Heightened Risk for Early-Onset Colorectal Cancer Among Younger Adult Patients

Researchers have identified four warning signs and symptoms that may indicate an elevated risk of early-onset colorectal cancer, according to a new study published by Fritz et al in the Journal of the National Cancer Institute. The findings may be key to helping physicians more effectively detect...

lung cancer

Novel AI Model Offers Potential for Earlier Lung Cancer Diagnoses

A new artificial intelligence (AI) model could help physicians diagnose lung cancer earlier, according to a study published by Hunter et al in eBioMedicine. The findings suggested that the new model may yield a diagnosis more quickly and potentially more accurately than two existing risk assessment ...

breast cancer

Judy C. Boughey, MD, on Changes in Axillary Surgical Management: An I-SPY2 Analysis

Judy C. Boughey, MD, of the Mayo Clinic, discusses the decrease, over the past decade, of axillary lymph node dissection, especially in patients with node-positive breast cancer at diagnosis who had sentinel lymph node surgery after neoadjuvant chemotherapy. These findings are based on the records...

breast cancer

pCR and Individual Patient Prognosis After Neoadjuvant Chemotherapy and Anti-HER2 Therapy in HER2-Positive Early Breast Cancer

In an analysis reported in the Journal of Clinical Oncology, Marion T. van Mackelenbergh, MD, PhD, and colleagues found that patients with early HER2-positive breast cancer who achieved pathologic complete response (pCR) on neoadjuvant chemotherapy plus anti-HER2 treatment had better overall and...

breast cancer

Novel Imaging Agent May Help Surgeons Detect Residual Tumor Tissue Following Breast-Conserving Surgery

Researchers have discovered that the investigational optical imaging agent pegulicianine in fluorescence-guided surgery (pFGS) may have been effective at helping surgeons identify and remove residual tumor tissue in patients with breast cancer during breast-conserving surgery, according to a novel...

cns cancers
issues in oncology

Economic Hardship May Be Predictive of Neurocognitive Outcomes in Pediatric Patients Undergoing Radiation Therapy

Researchers have found that pediatric patients with cancer undergoing radiation therapy may experience greater baseline and long-term neurocognitive outcomes when they have supportive environments compared with those who live in neighborhoods with economic hardship, according to a new study...

leukemia
genomics/genetics

Addition of Blinatumomab to Chemotherapy in Infant Patients With KMT2A-Rearranged ALL

In a phase II trial reported in The New England Journal of Medicine, van der Sluis et al found that the addition of blinatumomab—a bispecific T-cell engager molecule targeting CD19—to standard chemotherapy appeared to result in marked improvements in outcome among infants with KMT2A-rearranged...

gastroesophageal cancer
gastrointestinal cancer

First-Line Zolbetuximab Plus mFOLFOX6 in CLDN18.2-Positive, HER2-Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

As reported in The Lancet by Kohei Shitara, MD, and colleagues, the phase III SPOTLIGHT trial has shown significantly prolonged progression-free and overall survival with the addition of the anti–claudin-18 isoform 2 (CLDN18.2) antibody zolbetuximab to mFOLFOX6 (modified leucovorin [or...

gynecologic cancers

Updated Analysis of Study 309/KEYNOTE-775: Lenvatinib Plus Pembrolizumab in Previously Treated Patients With Advanced Endometrial Cancer

As reported in the Journal of Clinical Oncology by Vicky Makker, MD, and colleagues, an updated analysis of the phase III Study 309/KEYNOTE-775 trial showed overall and progression-free survival benefits with lenvatinib/pembrolizumab vs physician’s choice of chemotherapy among previously treated...

covid-19
breast cancer
colorectal cancer

Lifestyle Habits, Risk Factors, and Cancer Screening During COVID-19 Pandemic

Investigators discovered both favorable and unfavorable changes in major cancer risk factors, preventive behaviors and services, and screenings in the United States during the COVID-19 pandemic, according to a new study published by Star et al in Cancer Epidemiology, Biomarkers & Prevention....

breast cancer
supportive care
cost of care

Remote Outreach May Increase Uptake of and Adherence to Cancer Screenings in Females in Rural Settings

Females in rural areas may be six times more likely to receive timely breast, cervical, and colorectal cancer screenings with remote outreach that involves interactive education and follow-up support by telephone compared with females in rural areas who don’t have remote outreach, according to a...

skin cancer
genomics/genetics

Researchers Study Genetic Changes Across Multiple Organs of Metastatic Melanoma

Researchers have found that studying the landscape of DNA and RNA alterations across multiple organs of metastasis may provide a new direction in cancer therapeutics to address treatment failure, according to a new study published by Liu et al in Nature Medicine. The new findings from analyzing...

breast cancer
issues in oncology

Preoperative MRI Scans May Not Reduce Positive Margins and Reoperations in Patients With Breast Cancer Undergoing Lumpectomy

Preoperative magnetic resonance imaging (MRI) scans were not associated with a reduction in positive margins at the tumor site or in the need to reoperate to help ensure complete tumor excision in patients with breast cancer undergoing lumpectomy, according to new findings presented by Cairns et al ...

survivorship

Cardiovascular Disease in Survivors of Testicular Cancer

In a Dutch study reported in the Journal of Clinical Oncology, Lubberts et al identified risk factors for cardiovascular disease among survivors of testicular cancer and assessed the impact of cardiovascular disease on quality of life. Study Details The study involved data from a multicenter cohort ...

breast cancer
issues in oncology

Intraoperative vs Postoperative Lymph Node Pathology Evaluation in Patients With Breast Cancer Undergoing Mastectomy

Patients who underwent pathology evaluation of their sentinel lymph nodes during mastectomy surgery may have been significantly more likely to receive aggressive nodal therapy than patients whose lymph node biopsies and treatment strategies were evaluated after surgery. The new findings were...

breast cancer
supportive care

Exercise and Wellness Programs May Enhance Well-Being and Reduce Health-Care Costs in Patients With Breast Cancer

Two new studies revealed that specialized exercise and wellness programs may significantly increase physical well-being and quality of life as well as reduce health-care costs in patients with breast cancer, according to findings presented by Wonders et al and Brahmbhatt et al at the 24th American...

breast cancer
geriatric oncology

Does Surveillance Mammography Benefit Geriatric Patients With Breast Cancer?

Investigators have found that undergoing an annual surveillance mammography may remain common among geriatric patients with breast cancer, even in those with only a small risk of developing a second primary tumor or with significant competing mortality risks as a result of advanced age and...

cns cancers

Response Assessment in Neuro-Oncology Criteria in Determining Correlation of Survival Outcomes in Glioblastoma

In a study reported in the Journal of Clinical Oncology, Youssef et al found that the standard Response Assessment in Neuro-Oncology (RANO) and modified RANO (mRANO) criteria produced similar correlations between progression-free survival and overall survival in newly diagnosed glioblastoma and...

Advertisement

Advertisement




Advertisement